A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment

OBJECTIVE: The objective of this study was to examine clinicians' patient selection and result interpretation of a clinically validated mass spectrometry test measuring amyloid beta and ApoE blood biomarkers combined with patient age (PrecivityAD® blood test) in symptomatic patients evaluated f...

Descripción completa

Detalles Bibliográficos
Autores principales: Monane, Mark, Johnson, Kim G., Snider, B. Joy, Turner, Raymond S., Drake, Jonathan D., Maraganore, Demetrius M., Bicksel, James L., Jacobs, Daniel H., Ortega, Julia L., Henderson, Joni, Jiang, Yan, Huang, Shuguang, Coppinger, Justine, Fogelman, Ilana, West, Tim, Braunstein, Joel B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578891/
https://www.ncbi.nlm.nih.gov/pubmed/37550958
http://dx.doi.org/10.1002/acn3.51863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578891/
https://www.ncbi.nlm.nih.gov/pubmed/37550958
http://dx.doi.org/10.1002/acn3.51863

Ejemplares similares